Drug: Normal Saline

Phase 3

PPharmazz, Inc.

Drug: Normal Saline is one of 6 therapeutic programs targeting Acute Ischemic Stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Acute Ischemic StrokeRecruiting

Acute Ischemic StrokePhase 3

Recruiting

Competition

Competitive Landscape

12 competitors in Acute Ischemic Stroke

#DrugCompanyPhaseTrials

Low-Dose Tenecteplase Intravenous Thrombolysis

SSouthwest Hospital, China

Approved

1 2

Standard-Dose Tenecteplase Intravenous Thrombolysis

SSouthwest Hospital, China

Approved

1 3

Sovateltide

PPharmazz, Inc.

Phase 3

1 4

Drug: Normal Saline

PPharmazz, Inc.

Phase 3

1 5

Prourokinase

SSuzhou Landing Pharmaceuticals

Phase 2

1 6

Sivelestat Sodium

TThe First Hospital of Jilin University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Acute Ischemic Stroke

NCT05691244

Clinical

Trials by Indication[1]

Acute Ischemic Stroke1 trial

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke.

Recruiting·PPharmazz, Inc.·Phase 3·NCT05691244·514 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug: Normal Saline. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Drug: Normal Saline. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Pharmazz, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: PPharmazz, Inc.

Drug: Normal Saline

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute Ischemic Stroke1 trial

References

Drug Info

Quick Facts

Related News